Guardant Health Receives FDA Approval for Guardant360^® CDx as Companion Diagnostic for BRAFTOVI^® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Guardant Health, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360^® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with BRAFTOVI^® in combination with cetuximab and chemotherapy in accordance with the approved product labeling.